SRZN תחזית צמיחת רווח נקי למניה לשנה הבאה surrozen.com

The forward-looking EPS growth vector for next year reflects expert expectations, while 69.30 shows the current value of the metric. Surrozen, Inc. (SRZN) develops tissue regeneration therapies via Wnt signaling, funding research into intestinal and liver diseases. The business model minimizes costs by outsourcing trials to external CROs. Unique patents for specific antibodies provide the company's technological edge.

This indicator captures the market consensus regarding the growth rate of earnings per share, reflecting aggregate expert expectations for future returns. Calculated values are based on current forecasts; therefore, the current projected EPS growth for the next period serves as a gauge of market confidence in the company's success. For Surrozen, Inc. (SRZN), this trend is driven exclusively by the results of stem cell clinical trials, ignoring external macroeconomic factors.